Sugammadex sodium
Active Pharmaceutical Ingredients 2025-03-03
Sugammadex sodium γ-Cyclodextrin, 6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-, sodium salt (1:8)
Catalog ID100883
CAS NO.343306-79-6
Purity 95%
MDL NumberMFCD09954145
EINEC Molecular FormulaC72H104O48S8.8Na
Molecular Weight2178.01
| Category | Content |
|---|---|
| Generic Name | Sugammadex Sodium |
| Brand Name | Bridion |
| Chemical Formula | C72H104Na8O48S8 |
| Mechanism of Action | Sugammadex is a modified gamma-cyclodextrin that encapsulates neuromuscular blocking drugs (NMBDs) such as rocuronium and vecuronium, preventing them from acting at the acetylcholine receptor. This rapidly reverses neuromuscular blockade. |
| Indications | Approved for antagonism of rocuronium- and vecuronium-induced neuromuscular blockade in adults. |
| Dosage Forms | Intravenous solution |
| Administration | Rapid intravenous injection (within 10 seconds) after the reappearance of the second twitch in the train-of-four. |
| Side Effects | – Common: Headache, nausea, vomiting, injection site pain, dizziness.<br>- Serious: Hypotension, bradycardia, anaphylaxis, respiratory complications. |
| Contraindications | Hypersensitivity to sugammadex sodium or any excipients. |
| Special Populations | – Not recommended in severe renal impairment or dialysis patients.<br>- No dose adjustment needed in mild-to-moderate renal or hepatic impairment. |
| Developer | Merck & Co. (Market as Bridion) |
| Approval Date | Approved by the FDA in 2015 |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
